[O-33] Clinical trial and Regenerative medicine2

[O-33-1] Efficacy and safety of satralizumab (SA237) as add-on therapy for NMOSD: Results from Phase 3 study

Takashi Yamamura¹, Ingo Kleiter², Kazuo Fujihara³, Jacqueline Palace⁴, Greenberg Benjamin⁵, Beata Zakrzewska-pniewska⁶, Francesco Patti⁷, Tsai Ching-piao⁸, Albert Saiz⁹, Yusuke Terada¹⁰, Yuichi Kawata¹⁰, Padraig Wright¹¹, Jerome De Seze¹² (1.Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan, 2.Department of Neurology, Ruhr University Bochum, Bochum, Germany, 3.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine and Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, 4.Department of Clinical Neurology, John Radcliffe Hospital, Oxford, United Kingdom, 5.Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA, 6.Department of Neurology, Warsaw Medical University, Warsaw, Poland, 7.Department G.F. Ingrassia-section of Neurosciences, University of Catania, Catania, Italy, 8.Neurological Institute, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, 9.Service of Neurology, Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 10.Chugai Pharmaceutical Co., Ltd, 11.Chugai Pharma Europe, 12.Department of Neurology, Hôpital de Hautepierre, Strasbourg Cedex, France)